Aurora Reports Q4 Adjusted EBITDA of $9.2M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2026
0mins
Reports Q4 adjusted EBITDA $9.2M vs. $14.1M last year. "During FY26, we exceeded our projection for global medical cannabis net revenue1 led by double-digit growth in Europe and delivered on our expectation for Adjusted EBITDA with both at record outcomes. Our performance validates Aurora's global medical cannabis strategy which has positioned us as a leading provider in Canada, Europe, Australia, and New Zealand," said CEO Miguel Martin. "We believe Aurora's leadership in medical cannabis is built upon our regulatory expertise, extensive and recently expanded supply network of EU-GMP certified facilities, and proven commercial execution. We are confident that these attributes create a competitive advantage as we navigate the evolving industry dynamics to maintain and expand global market share, while driving international growth".
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACB
Wall Street analysts forecast ACB stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.790
Low
6.28
Averages
6.77
High
7.39
Current: 2.790
Low
6.28
Averages
6.77
High
7.39
About ACB
Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company's segments include Cannabis and Plant Propagation. Its adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. The Company's medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others. The Company is engaged in distribution wholesale medical cannabis in various international markets, including Australia, New Zealand, and the Caribbean. It has manufacturing facilities in Canada and Germany.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aurora Cannabis Reports Strong FY 2026 Earnings Exceeding Guidance
- Significant Revenue Growth: Aurora Cannabis reported a net revenue of $321 million for FY 2026, marking an 11% increase that exceeded guidance by $8 million, demonstrating the company's strong market performance and growth potential.
- Adjusted EBITDA Improvement: The adjusted EBITDA grew by 32% year-over-year to $54 million, reflecting the company's success in cost control and operational efficiency, which is expected to lay a solid foundation for future profitability.
- Strong Balance Sheet: Aurora ended the fiscal year with $165 million in cash and no debt, providing ample financial flexibility for future expansions and investments, thereby enhancing its competitive position in the market.
- Market Challenges and Opportunities: Despite anticipating a 30% revenue decline in FY 2027 due to lower reimbursement rates, Aurora is strategically acquiring Safari Flower Co. to bolster its GMP capabilities in the German market, showcasing its determination to seek growth amid adversity.
See More
Aurora Cannabis Reports Q4 Results with Weak FY27 Outlook
- Revenue Decline Expected: Aurora Cannabis anticipates a revenue decline for FY27, projecting total net revenue to revert to FY25 levels due to headwinds in its Canadian medical cannabis unit, primarily from reduced government-reimbursed pricing, which could hinder future growth potential.
- Strong Financial Performance: Despite achieving C$320.6M in net revenue for FY26, an 11% YoY increase, and an 18% rise in global medical cannabis revenue to C$288.6M, the company forecasts a decline in adjusted EBITDA for FY27, indicating uncertainty in future profitability.
- Q4 Revenue Exceeds Expectations: In Q4, Aurora reported net revenue of C$84.8M, reflecting a 10% YoY growth that surpassed analysts' expectations of C$75.7M, showcasing strong performance in the medical cannabis sector, particularly in Germany and Poland.
- Consumer Sales Plummet: While the medical cannabis segment generated C$77.1M in revenue with a 14% YoY increase, consumer cannabis sales fell sharply by 55% to C$3.6M, highlighting shifts in market demand and intensified competitive challenges.
See More
Aurora Cannabis Exceeds Fiscal Year 2026 Revenue Expectations
- Financial Performance Highlights: In fiscal year 2026, Aurora achieved global medical cannabis net revenue of CAD 84.8 million, a 10% increase year-over-year, primarily driven by double-digit growth in Europe, showcasing the company's robust performance in the global medical cannabis market.
- Medical Cannabis Revenue Growth: Medical cannabis net revenue reached CAD 77.1 million, a 14% increase, accounting for 91% of the company's total Q4 revenue, reflecting expansion in the German and Polish markets and enhanced product offerings for insured patients in Canada, further solidifying Aurora's market leadership.
- Consumer Cannabis Business Contraction: Consumer cannabis net revenue fell to CAD 3.6 million, a 55% decline, primarily due to the company's strategic shift towards medical cannabis, reducing reliance on the low-margin consumer market, indicating Aurora's focus on higher-return opportunities.
- Adjusted Net Income Decline: Adjusted net income was CAD 5.6 million, a 63% decrease year-over-year, mainly due to increased SG&A expenses and reduced foreign exchange gains, highlighting the cost pressures and market challenges faced during the company's transformation.
See More
Aurora Cannabis Reports Record Revenue and EBITDA for FY2026
- Global Revenue Growth: Aurora Cannabis achieved a record net revenue of $288.6 million for FY2026, representing an 18% year-over-year increase, highlighting the company's strong growth in the European market and potential for international expansion.
- Record Adjusted EBITDA: The company reported an adjusted EBITDA of $53.8 million for FY2026, a 32% increase from the previous year, reflecting effective operations and cost control in high-margin markets.
- Strategic Acquisition: In April 2026, Aurora acquired Safari Flower Company for $26.5 million, enhancing its production capacity in international markets, which is expected to drive future revenue growth.
- Strong Balance Sheet: As of March 31, 2026, Aurora held approximately $164.7 million in cash and short-term investments with no debt, ensuring financial flexibility for future expansions and investments.
See More
Aurora Cannabis Q4 Earnings Beat Expectations with Strong Revenue Growth
- Strong Financial Performance: Aurora Cannabis reported an adjusted net income of C$5.6 million in Q4, indicating a continued improvement in profitability as the company navigates a competitive market landscape.
- Significant Revenue Growth: The company achieved revenue of C$84.82 million in Q4, reflecting a 10.5% year-over-year increase and surpassing market expectations by C$9.4 million, demonstrating robust product demand and a steady increase in market share.
- Positive Market Reaction: The recent DEA rescheduling of cannabis has led to a positive market response, boosting Aurora Cannabis's stock price and reflecting investor confidence in the company's future growth potential.
- Optimistic Industry Outlook: With an improving regulatory environment for the cannabis industry, Aurora Cannabis is well-positioned to benefit from market expansion and increasing consumer demand, further solidifying its position within the sector.
See More
Aurora Cannabis Q4 Earnings Preview Indicates Loss
- Earnings Forecast: Aurora Cannabis is set to report its Q4 results on June 11, with analysts projecting a loss of C$0.14 per share and revenue around C$75.42M, indicating significant financial challenges ahead.
- Market Exit Impact: Analysts note that the company's exit from low-margin Canadian markets is expected to create volatility in the quarterly results, potentially leading to write-downs on consumer-facing assets, which could adversely affect overall performance.
- Safari Flower Acquisition: In April, Aurora announced the acquisition of Safari Flower Company for approximately C$26.5M, which is anticipated to contribute positively to adjusted EBITDA in fiscal year 2027, reflecting the company's strategic focus on future growth opportunities.
- Annual Outlook: The firm is expected to report a full-year loss of -$0.70 per share on revenue of C$358.62M, despite expectations for year-over-year growth in global medical cannabis net revenue, showcasing its competitive position in the industry.
See More
Aurora Cannabis Reports Strong FY 2026 Earnings Exceeding Guidance
- Significant Revenue Growth: Aurora Cannabis reported a net revenue of $321 million for FY 2026, marking an 11% increase that exceeded guidance by $8 million, demonstrating the company's strong market performance and growth potential.
- Adjusted EBITDA Improvement: The adjusted EBITDA grew by 32% year-over-year to $54 million, reflecting the company's success in cost control and operational efficiency, which is expected to lay a solid foundation for future profitability.
- Strong Balance Sheet: Aurora ended the fiscal year with $165 million in cash and no debt, providing ample financial flexibility for future expansions and investments, thereby enhancing its competitive position in the market.
- Market Challenges and Opportunities: Despite anticipating a 30% revenue decline in FY 2027 due to lower reimbursement rates, Aurora is strategically acquiring Safari Flower Co. to bolster its GMP capabilities in the German market, showcasing its determination to seek growth amid adversity.
See More
Aurora Cannabis Reports Q4 Results with Weak FY27 Outlook
- Revenue Decline Expected: Aurora Cannabis anticipates a revenue decline for FY27, projecting total net revenue to revert to FY25 levels due to headwinds in its Canadian medical cannabis unit, primarily from reduced government-reimbursed pricing, which could hinder future growth potential.
- Strong Financial Performance: Despite achieving C$320.6M in net revenue for FY26, an 11% YoY increase, and an 18% rise in global medical cannabis revenue to C$288.6M, the company forecasts a decline in adjusted EBITDA for FY27, indicating uncertainty in future profitability.
- Q4 Revenue Exceeds Expectations: In Q4, Aurora reported net revenue of C$84.8M, reflecting a 10% YoY growth that surpassed analysts' expectations of C$75.7M, showcasing strong performance in the medical cannabis sector, particularly in Germany and Poland.
- Consumer Sales Plummet: While the medical cannabis segment generated C$77.1M in revenue with a 14% YoY increase, consumer cannabis sales fell sharply by 55% to C$3.6M, highlighting shifts in market demand and intensified competitive challenges.
See More
Aurora Cannabis Exceeds Fiscal Year 2026 Revenue Expectations
- Financial Performance Highlights: In fiscal year 2026, Aurora achieved global medical cannabis net revenue of CAD 84.8 million, a 10% increase year-over-year, primarily driven by double-digit growth in Europe, showcasing the company's robust performance in the global medical cannabis market.
- Medical Cannabis Revenue Growth: Medical cannabis net revenue reached CAD 77.1 million, a 14% increase, accounting for 91% of the company's total Q4 revenue, reflecting expansion in the German and Polish markets and enhanced product offerings for insured patients in Canada, further solidifying Aurora's market leadership.
- Consumer Cannabis Business Contraction: Consumer cannabis net revenue fell to CAD 3.6 million, a 55% decline, primarily due to the company's strategic shift towards medical cannabis, reducing reliance on the low-margin consumer market, indicating Aurora's focus on higher-return opportunities.
- Adjusted Net Income Decline: Adjusted net income was CAD 5.6 million, a 63% decrease year-over-year, mainly due to increased SG&A expenses and reduced foreign exchange gains, highlighting the cost pressures and market challenges faced during the company's transformation.
See More
Aurora Cannabis Reports Record Revenue and EBITDA for FY2026
- Global Revenue Growth: Aurora Cannabis achieved a record net revenue of $288.6 million for FY2026, representing an 18% year-over-year increase, highlighting the company's strong growth in the European market and potential for international expansion.
- Record Adjusted EBITDA: The company reported an adjusted EBITDA of $53.8 million for FY2026, a 32% increase from the previous year, reflecting effective operations and cost control in high-margin markets.
- Strategic Acquisition: In April 2026, Aurora acquired Safari Flower Company for $26.5 million, enhancing its production capacity in international markets, which is expected to drive future revenue growth.
- Strong Balance Sheet: As of March 31, 2026, Aurora held approximately $164.7 million in cash and short-term investments with no debt, ensuring financial flexibility for future expansions and investments.
See More
Aurora Cannabis Q4 Earnings Beat Expectations with Strong Revenue Growth
- Strong Financial Performance: Aurora Cannabis reported an adjusted net income of C$5.6 million in Q4, indicating a continued improvement in profitability as the company navigates a competitive market landscape.
- Significant Revenue Growth: The company achieved revenue of C$84.82 million in Q4, reflecting a 10.5% year-over-year increase and surpassing market expectations by C$9.4 million, demonstrating robust product demand and a steady increase in market share.
- Positive Market Reaction: The recent DEA rescheduling of cannabis has led to a positive market response, boosting Aurora Cannabis's stock price and reflecting investor confidence in the company's future growth potential.
- Optimistic Industry Outlook: With an improving regulatory environment for the cannabis industry, Aurora Cannabis is well-positioned to benefit from market expansion and increasing consumer demand, further solidifying its position within the sector.
See More
Aurora Cannabis Q4 Earnings Preview Indicates Loss
- Earnings Forecast: Aurora Cannabis is set to report its Q4 results on June 11, with analysts projecting a loss of C$0.14 per share and revenue around C$75.42M, indicating significant financial challenges ahead.
- Market Exit Impact: Analysts note that the company's exit from low-margin Canadian markets is expected to create volatility in the quarterly results, potentially leading to write-downs on consumer-facing assets, which could adversely affect overall performance.
- Safari Flower Acquisition: In April, Aurora announced the acquisition of Safari Flower Company for approximately C$26.5M, which is anticipated to contribute positively to adjusted EBITDA in fiscal year 2027, reflecting the company's strategic focus on future growth opportunities.
- Annual Outlook: The firm is expected to report a full-year loss of -$0.70 per share on revenue of C$358.62M, despite expectations for year-over-year growth in global medical cannabis net revenue, showcasing its competitive position in the industry.
See More
